Cargando…

Modeling Cancer Cell Growth Dynamics In vitro in Response to Antimitotic Drug Treatment

Investigating the role of intrinsic cell heterogeneity emerging from variations in cell-cycle parameters and apoptosis is a crucial step toward better informing drug administration. Antimitotic agents, widely used in chemotherapy, target exclusively proliferative cells and commonly induce a prolonge...

Descripción completa

Detalles Bibliográficos
Autores principales: Lorz, Alexander, Botesteanu, Dana-Adriana, Levy, Doron
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582072/
https://www.ncbi.nlm.nih.gov/pubmed/28913178
http://dx.doi.org/10.3389/fonc.2017.00189
_version_ 1783261122882699264
author Lorz, Alexander
Botesteanu, Dana-Adriana
Levy, Doron
author_facet Lorz, Alexander
Botesteanu, Dana-Adriana
Levy, Doron
author_sort Lorz, Alexander
collection PubMed
description Investigating the role of intrinsic cell heterogeneity emerging from variations in cell-cycle parameters and apoptosis is a crucial step toward better informing drug administration. Antimitotic agents, widely used in chemotherapy, target exclusively proliferative cells and commonly induce a prolonged mitotic arrest followed by cell death via apoptosis. In this paper, we developed a physiologically motivated mathematical framework for describing cancer cell growth dynamics that incorporates the intrinsic heterogeneity in the time individual cells spend in the cell-cycle and apoptosis process. More precisely, our model comprises two age-structured partial differential equations for the proliferative and apoptotic cell compartments and one ordinary differential equation for the quiescent compartment. To reflect the intrinsic cell heterogeneity that governs the growth dynamics, proliferative and apoptotic cells are structured in “age,” i.e., the amount of time remaining to be spent in each respective compartment. In our model, we considered an antimitotic drug whose effect on the cellular dynamics is to induce mitotic arrest, extending the average cell-cycle length. The prolonged mitotic arrest induced by the drug can trigger apoptosis if the time a cell will spend in the cell cycle is greater than the mitotic arrest threshold. We studied the drug’s effect on the long-term cancer cell growth dynamics using different durations of prolonged mitotic arrest induced by the drug. Our numerical simulations suggest that at confluence and in the absence of the drug, quiescence is the long-term asymptotic behavior emerging from the cancer cell growth dynamics. This pattern is maintained in the presence of small increases in the average cell-cycle length. However, intermediate increases in cell-cycle length markedly decrease the total number of cells and can drive the cancer population to extinction. Intriguingly, a large “switch-on/switch-off” increase in the average cell-cycle length maintains an active cell population in the long term, with oscillating numbers of proliferative cells and a relatively constant quiescent cell number.
format Online
Article
Text
id pubmed-5582072
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-55820722017-09-14 Modeling Cancer Cell Growth Dynamics In vitro in Response to Antimitotic Drug Treatment Lorz, Alexander Botesteanu, Dana-Adriana Levy, Doron Front Oncol Oncology Investigating the role of intrinsic cell heterogeneity emerging from variations in cell-cycle parameters and apoptosis is a crucial step toward better informing drug administration. Antimitotic agents, widely used in chemotherapy, target exclusively proliferative cells and commonly induce a prolonged mitotic arrest followed by cell death via apoptosis. In this paper, we developed a physiologically motivated mathematical framework for describing cancer cell growth dynamics that incorporates the intrinsic heterogeneity in the time individual cells spend in the cell-cycle and apoptosis process. More precisely, our model comprises two age-structured partial differential equations for the proliferative and apoptotic cell compartments and one ordinary differential equation for the quiescent compartment. To reflect the intrinsic cell heterogeneity that governs the growth dynamics, proliferative and apoptotic cells are structured in “age,” i.e., the amount of time remaining to be spent in each respective compartment. In our model, we considered an antimitotic drug whose effect on the cellular dynamics is to induce mitotic arrest, extending the average cell-cycle length. The prolonged mitotic arrest induced by the drug can trigger apoptosis if the time a cell will spend in the cell cycle is greater than the mitotic arrest threshold. We studied the drug’s effect on the long-term cancer cell growth dynamics using different durations of prolonged mitotic arrest induced by the drug. Our numerical simulations suggest that at confluence and in the absence of the drug, quiescence is the long-term asymptotic behavior emerging from the cancer cell growth dynamics. This pattern is maintained in the presence of small increases in the average cell-cycle length. However, intermediate increases in cell-cycle length markedly decrease the total number of cells and can drive the cancer population to extinction. Intriguingly, a large “switch-on/switch-off” increase in the average cell-cycle length maintains an active cell population in the long term, with oscillating numbers of proliferative cells and a relatively constant quiescent cell number. Frontiers Media S.A. 2017-08-30 /pmc/articles/PMC5582072/ /pubmed/28913178 http://dx.doi.org/10.3389/fonc.2017.00189 Text en Copyright © 2017 Lorz, Botesteanu and Levy. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Lorz, Alexander
Botesteanu, Dana-Adriana
Levy, Doron
Modeling Cancer Cell Growth Dynamics In vitro in Response to Antimitotic Drug Treatment
title Modeling Cancer Cell Growth Dynamics In vitro in Response to Antimitotic Drug Treatment
title_full Modeling Cancer Cell Growth Dynamics In vitro in Response to Antimitotic Drug Treatment
title_fullStr Modeling Cancer Cell Growth Dynamics In vitro in Response to Antimitotic Drug Treatment
title_full_unstemmed Modeling Cancer Cell Growth Dynamics In vitro in Response to Antimitotic Drug Treatment
title_short Modeling Cancer Cell Growth Dynamics In vitro in Response to Antimitotic Drug Treatment
title_sort modeling cancer cell growth dynamics in vitro in response to antimitotic drug treatment
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5582072/
https://www.ncbi.nlm.nih.gov/pubmed/28913178
http://dx.doi.org/10.3389/fonc.2017.00189
work_keys_str_mv AT lorzalexander modelingcancercellgrowthdynamicsinvitroinresponsetoantimitoticdrugtreatment
AT botesteanudanaadriana modelingcancercellgrowthdynamicsinvitroinresponsetoantimitoticdrugtreatment
AT levydoron modelingcancercellgrowthdynamicsinvitroinresponsetoantimitoticdrugtreatment